Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease Article (Faculty180)

cited authors

  • Xie, Jeffrey X; Alderson, Helen; Ritchie, James; Kalra, Philip A; Xie, Yanmei; Ren, Kaili; Nguyen, Hanh; Chen, Tian; Brewster, Pamela; Gupta, Rajesh; Dworkin, Lance D; Malhotra, Deepak; Cooper, Christopher J; Tian, Jiang; Haller, S T


  • Soluble CD40 ligand (sCD40L) has been implicated in the development of renal injury. The CD40 receptor exists in a soluble form, sCD40R, and has been shown to function as a competitive antagonist against CD40 activation. We analyzed whether plasma levels of sCD40L and sCD40R predict changes in renal function in an all-cause chronic kidney disease (CKD) cohort. Stratification of subjects based on sCD40L and sCD40R individually, as well as in combination, demonstrated that sCD40L was directly associated with declines in estimated glomerular filtration rate (eGFR). sCD40R was negatively associated with declines in eGFR. Baseline characteristics following stratification, including systolic blood pressure, history of diabetes mellitus or peripheral vascular disease, primary renal disease classification, and angiotensin converting enzyme inhibitor or angiotensin receptor blocker usage were not significantly different. High sCD40L and low sCD40R were both found to be independent predictors of a decline in eGFR at 1-year follow-up (-7.57%, pā€‰=ā€‰0.014; -6.39%, pā€‰=ā€‰0.044). Our data suggest that circulating levels of sCD40L and sCD40R are associated with changes in renal function in patients with CKD. The CD40 decoy receptor, sCD40R, may serve as a potential therapeutic target to attenuate renal function decline.

publication date

  • 2017

published in

start page

  • 7942


  • 7